X4 Pharmaceuticals(XFOR)

Focus: X4 Pharmaceuticals is a Boston-based public biotech focused on oral small-molecule therapeutics, primarily in neurology and immunology. The company is in clinical-stage development with no marketed products.

Neurology

Profile data last refreshed 8h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

Should You Work at X4 Pharmaceuticals?

AI assessment

X4 offers clinical-stage upside and a near-term regulatory catalyst, but severe cash constraints and minimal hiring suggest limited near-term career growth and organizational fluidity risks.

Why Work Here

Lead pipeline program Mavorixafor has reached Phase 3 for both Neutropenia and WHIM Syndrome, with recent FDA approval signaled in May 2026 representing a major clinical validation milestone.

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$0K

Pipeline & Clinical Trials

No intervention

WHIM Syndrome

N/A

Clinical Trials (1)

NCT03087370A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome

N/A

Help build intelligence for X4 Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline across oncology (clear cell renal cell carcinoma, melanoma) and rare immunology indications suggests exposure to multiple therapeutic areas and career development paths.

Public company status with active stock market presence provides transparency, equity upside potential, and institutional stability compared to private-stage peers.

Watch Out For

Significant cash burn: FY2025 net loss of $101M on $72M R&D spend, with cash declining from $122M to $56M year-over-year—runway concerns may emerge within 12-18 months without revenue or fundraising.
Minimal hiring activity (only 1 open role reported) and zero publications suggest either a very lean organization or reduced investment in growth and scientific visibility.
Thin stock trading and recent CFO share sales (July 2026) signal potential shareholder uncertainty despite the recent FDA approval news.

Generated by Claude from X4 Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

X4P-001

Healthy

PHASE_1

Clinical Trials (1)

NCT02680782A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Phase 1

Mavorixafor

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT06914869Drug-Drug Interaction Potential of Mavorixafor

Phase 1

X4P-001

Melanoma

PHASE_1

Clinical Trials (1)

NCT02823405X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

Phase 1

Mavorixafor

Hepatic Insufficiency

PHASE_1

Clinical Trials (1)

NCT06858696A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Phase 1

Mavorixafor

Waldenstrom's Macroglobulinemia

PHASE_1

Clinical Trials (1)

NCT04274738A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Phase 1

X4P-001

Clear Cell Renal Cell Carcinoma

PHASE_1_2

Clinical Trials (1)

NCT02667886Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

Phase 1/2

Mavorixafor

Neutropenia

PHASE_1_2

Clinical Trials (1)

NCT04154488A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Phase 1/2

X4P-001

Clear Cell Renal Cell Carcinoma

PHASE_1_2

Clinical Trials (1)

NCT02923531Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

Phase 1/2

X4P-001

WHIM Syndrome

PHASE_2

Clinical Trials (1)

NCT03005327A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Phase 2

Mavorixafor

Neutropenia

PHASE_3

Clinical Trials (1)

NCT06056297A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Phase 3

Mavorixafor

WHIM Syndrome

PHASE_3

Clinical Trials (1)

NCT03995108Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Phase 3

Interview Prep Quick Facts

Founded: 2013

Portfolio: 12 clinical trials

Top TAs: Oncology, Gastroenterology

SEC Filings: 2 available

Open Roles: 1 active job

Therapeutic Area Focus

Oncology

3 pipeline

Gastroenterology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

R&D Spend

$72M18%

Net Income

-$101M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

X4 Pharmaceuticals(XFOR)

Should You Work at X4 Pharmaceuticals?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · X4 Pharmaceuticals(10)

Open Jobs (1)

Senior Director, Supply Chain & Logistics

Financials (FY2025)

Hiring Trend